Fundamental and Clinical Studies on Aztreonam in Pediatrics

Keisuke Sunakawa; Nobuo Saito; Yugo Ishizuka; Satoshi Iwata; Yoshitake Sato; Hironobu Akita

doi:10.11553/antibiotics1968b.38.3230

Fundamental and Clinical Studies on Aztreonam in Pediatrics

Keisuke Sunakawa, Nobuo Saito, Yugo Ishizuka, Satoshi Iwata, Yoshitake Sato, Hironobu Akita

Department of Infectious Diseases

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Fundamental and clinical results of AZT in pediatrics were as follows. 1. Pharmacokinetics of AZT was studied for 1 case with resulting high serum concentration and a halflife of approximate 1 hour. 2. AZT was administered to 10 patients with bacterial infections with 100% clinical efficacy and 62.5% bacterial elimination. Side effect was 1 case of diarrhea. 3. There were no abnormal laboratory or coagulation test findings nor vitamin K deficiency, platelet hypofunction or effects on intestinal bacterial flora. AZT was considered to be high in safety. 4. The administration of 20 mg/kg AZT 3 times a day was considered to be an effective treatment for pediatric Gram-negative infections.

Original language	English
Pages (from-to)	3230-3238
Number of pages	9
Journal	the japanese journal of antibiotics
Volume	38
Issue number	11
DOIs	https://doi.org/10.11553/antibiotics1968b.38.3230
Publication status	Published - 1985

ASJC Scopus subject areas

Microbiology (medical)
Pharmacology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11553/antibiotics1968b.38.3230

Cite this

@article{1e7e877519bc483487ea1c6d67715a19,

title = "Fundamental and Clinical Studies on Aztreonam in Pediatrics",

abstract = "Fundamental and clinical results of AZT in pediatrics were as follows. 1. Pharmacokinetics of AZT was studied for 1 case with resulting high serum concentration and a halflife of approximate 1 hour. 2. AZT was administered to 10 patients with bacterial infections with 100% clinical efficacy and 62.5% bacterial elimination. Side effect was 1 case of diarrhea. 3. There were no abnormal laboratory or coagulation test findings nor vitamin K deficiency, platelet hypofunction or effects on intestinal bacterial flora. AZT was considered to be high in safety. 4. The administration of 20 mg/kg AZT 3 times a day was considered to be an effective treatment for pediatric Gram-negative infections.",

author = "Keisuke Sunakawa and Nobuo Saito and Yugo Ishizuka and Satoshi Iwata and Yoshitake Sato and Hironobu Akita",

year = "1985",

doi = "10.11553/antibiotics1968b.38.3230",

language = "English",

volume = "38",

pages = "3230--3238",

journal = "the japanese journal of antibiotics",

issn = "0368-2781",

publisher = "Japan Antibiotics Research Association",

number = "11",

}

TY - JOUR

T1 - Fundamental and Clinical Studies on Aztreonam in Pediatrics

AU - Sunakawa, Keisuke

AU - Saito, Nobuo

AU - Ishizuka, Yugo

AU - Iwata, Satoshi

AU - Sato, Yoshitake

AU - Akita, Hironobu

PY - 1985

Y1 - 1985

N2 - Fundamental and clinical results of AZT in pediatrics were as follows. 1. Pharmacokinetics of AZT was studied for 1 case with resulting high serum concentration and a halflife of approximate 1 hour. 2. AZT was administered to 10 patients with bacterial infections with 100% clinical efficacy and 62.5% bacterial elimination. Side effect was 1 case of diarrhea. 3. There were no abnormal laboratory or coagulation test findings nor vitamin K deficiency, platelet hypofunction or effects on intestinal bacterial flora. AZT was considered to be high in safety. 4. The administration of 20 mg/kg AZT 3 times a day was considered to be an effective treatment for pediatric Gram-negative infections.

AB - Fundamental and clinical results of AZT in pediatrics were as follows. 1. Pharmacokinetics of AZT was studied for 1 case with resulting high serum concentration and a halflife of approximate 1 hour. 2. AZT was administered to 10 patients with bacterial infections with 100% clinical efficacy and 62.5% bacterial elimination. Side effect was 1 case of diarrhea. 3. There were no abnormal laboratory or coagulation test findings nor vitamin K deficiency, platelet hypofunction or effects on intestinal bacterial flora. AZT was considered to be high in safety. 4. The administration of 20 mg/kg AZT 3 times a day was considered to be an effective treatment for pediatric Gram-negative infections.

UR - http://www.scopus.com/inward/record.url?scp=0022413209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022413209&partnerID=8YFLogxK

U2 - 10.11553/antibiotics1968b.38.3230

DO - 10.11553/antibiotics1968b.38.3230

M3 - Article

C2 - 4094056

AN - SCOPUS:0022413209

SN - 0368-2781

VL - 38

SP - 3230

EP - 3238

JO - the japanese journal of antibiotics

JF - the japanese journal of antibiotics

IS - 11

ER -

Fundamental and Clinical Studies on Aztreonam in Pediatrics

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this